Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 21062927.
- Also identified by DOI 10.1158/1078-0432.CCR-10-2405.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine.
Medical subject headings
- Antineoplastic Agents
- ErbB Receptors
- Lung Neoplasms
- Molecular Targeted Therapy
- Mutation